Article
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
Blood - 24 Jan 2013
Giannoudis Athina, Wang Lihui, Jorgensen Andrea L, Xinarianos George, Davies Andrea, Pushpakom Sudeep, Liloglou Triantafilos, Zhang Jieying-Eunice, Austin Gemma, Holyoake Tessa L, Foroni Letizia, Kottaridis Panagiotis D, Müller Martin C, Pirmohamed Munir, Clark Richard E
Abstract excerpt
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is good, many fail to develop an optimal response or lose one. This heterogeneity could be attributed to the presence of human organic cation transporter-1 (hOCT1) single nucleotide polymorphisms (SNPs). In the present study, we analyzed the effect of 23 hOCT1 SNPs on imatinib treatment outcome in newly diagnosed CML patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.